BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31043528)

  • 1. CD4 Expression and Env Conformation Are Critical for HIV-1 Restriction by SERINC5.
    Zhang X; Shi J; Qiu X; Chai Q; Frabutt DA; Schwartz RC; Zheng YH
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31043528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5.
    Staropoli I; Dufloo J; Ducher A; Commere PH; Sartori-Rupp A; Novault S; Bruel T; Lorin V; Mouquet H; Schwartz O; Casartelli N
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5.
    Wu Y; Olety B; Weiss ER; Popova E; Yamanaka H; Göttlinger H
    mBio; 2019 Jun; 10(3):. PubMed ID: 31186327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV envelope tail truncation confers resistance to SERINC5 restriction.
    Haider T; Snetkov X; Jolly C
    Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34001619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIVcol Nef counteracts SERINC5 by promoting its proteasomal degradation but does not efficiently enhance HIV-1 replication in human CD4+ T cells and lymphoid tissue.
    Kmiec D; Akbil B; Ananth S; Hotter D; Sparrer KMJ; Stürzel CM; Trautz B; Ayouba A; Peeters M; Yao Z; Stagljar I; Passos V; Zillinger T; Goffinet C; Sauter D; Fackler OT; Kirchhoff F
    PLoS Pathog; 2018 Aug; 14(8):e1007269. PubMed ID: 30125328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Nef Antagonizes SERINC5 Restriction by Downregulation of SERINC5 via the Endosome/Lysosome System.
    Shi J; Xiong R; Zhou T; Su P; Zhang X; Qiu X; Li H; Li S; Yu C; Wang B; Ding C; Smithgall TE; Zheng YH
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The retroviral accessory proteins S2, Nef, and glycoMA use similar mechanisms for antagonizing the host restriction factor SERINC5.
    Ahmad I; Li S; Li R; Chai Q; Zhang L; Wang B; Yu C; Zheng YH
    J Biol Chem; 2019 Apr; 294(17):7013-7024. PubMed ID: 30862674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.
    Featherstone A; Aiken C
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32796070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.
    Heredia JD; Park J; Choi H; Gill KS; Procko E
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HIV-1 Env on SERINC5 Antagonism.
    Beitari S; Ding S; Pan Q; Finzi A; Liang C
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.
    Trautz B; Pierini V; Wombacher R; Stolp B; Chase AJ; Pizzato M; Fackler OT
    J Virol; 2016 Dec; 90(23):10915-10927. PubMed ID: 27681140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity to monoclonal antibody 447-52D and an open env trimer conformation correlate poorly with inhibition of HIV-1 infectivity by SERINC5.
    Angerstein AO; Stoneham CA; Ramirez PW; Guatelli JC; Vollbrecht T
    Virology; 2020 Sep; 548():73-81. PubMed ID: 32838948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection.
    Beitari S; Pan Q; Finzi A; Liang C
    J Virol; 2020 Jul; 94(16):. PubMed ID: 32493821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SERINC5 Restricts HIV-1 Infectivity by Promoting Conformational Changes and Accelerating Functional Inactivation of Env.
    Kirschman J; Marin M; Chen YC; Chen J; Herschhorn A; Smith AB; Melikyan GB
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AP-2 Adaptor Complex-Dependent Enhancement of HIV-1 Replication by Nef in the Absence of the Nef/AP-2 Targets SERINC5 and CD4.
    Olety B; Usami Y; Wu Y; Peters P; Göttlinger H
    mBio; 2023 Feb; 14(1):e0338222. PubMed ID: 36622146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SERINC5 Can Enhance Proinflammatory Cytokine Production by Primary Human Myeloid Cells in Response to Challenge with HIV-1 Particles.
    Pierini V; Gallucci L; Stürzel CM; Kirchhoff F; Fackler OT
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33597208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.
    Sood C; Marin M; Chande A; Pizzato M; Melikyan GB
    J Biol Chem; 2017 Apr; 292(14):6014-6026. PubMed ID: 28179429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Amino Acid Polymorphism within the HIV-1 Nef Dileucine Motif Functionally Uncouples Cell Surface CD4 and SERINC5 Downregulation.
    Mumby MJ; Johnson AL; Trothen SM; Edgar CR; Gibson R; Stathopulos PB; Arts EJ; Dikeakos JD
    J Virol; 2021 Jul; 95(16):e0058821. PubMed ID: 34037423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Conserved Acidic Residue in the C-Terminal Flexible Loop of HIV-1 Nef Contributes to the Activity of SERINC5 and CD4 Downregulation.
    Firrito C; Bertelli C; Rosa A; Chande A; Ananth S; van Dijk H; Fackler OT; Stoneham C; Singh R; Guatelli J; Pizzato M
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
    Chuang GY; Geng H; Pancera M; Xu K; Cheng C; Acharya P; Chambers M; Druz A; Tsybovsky Y; Wanninger TG; Yang Y; Doria-Rose NA; Georgiev IS; Gorman J; Joyce MG; O'Dell S; Zhou T; McDermott AB; Mascola JR; Kwong PD
    J Virol; 2017 May; 91(10):. PubMed ID: 28275193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.